1. Home
  2. MATH vs CTSO Comparison

MATH vs CTSO Comparison

Compare MATH & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalpha Technology Holding Limited

MATH

Metalpha Technology Holding Limited

HOLD

Current Price

$2.84

Market Cap

145.4M

Sector

Finance

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.73

Market Cap

49.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATH
CTSO
Founded
2015
1997
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.4M
49.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MATH
CTSO
Price
$2.84
$0.73
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
112.5K
126.1K
Earning Date
12-05-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.41
N/A
Revenue
$44,567,257.00
$36,979,520.00
Revenue This Year
N/A
$9.51
Revenue Next Year
N/A
$24.40
P/E Ratio
$6.93
N/A
Revenue Growth
165.86
23.89
52 Week Low
$0.88
$0.60
52 Week High
$4.17
$1.61

Technical Indicators

Market Signals
Indicator
MATH
CTSO
Relative Strength Index (RSI) 47.36 46.64
Support Level $2.68 $0.70
Resistance Level $3.03 $0.85
Average True Range (ATR) 0.21 0.07
MACD 0.01 0.01
Stochastic Oscillator 49.28 52.04

Price Performance

Historical Comparison
MATH
CTSO

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: